Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 349 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Long-term outcomes Clear all

Conditions: Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Interventions: Epanova® (omega-3 carboxylic acids), corn oil control; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 13,078 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 229
States / cities: Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more

Conditions: Breast Cancer, Insomnia, Weight Gain
Interventions: Cognitive-Behavioral Therapy for Insomnia (CBT-I), Sleep Education Control (EDU); Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland • Lutherville, Maryland

Conditions: Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Diabetes Self-Management Training (DSMT), Remote Glucose Monitoring (RGM), Community Health Worker tailored support; Behavioral
Lead sponsor: Sinai Health System; Other
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Cyclic Vomiting Syndrome
Interventions: Heartfulness meditation; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Serious Injury, Communication
Interventions: Best Case/Worst Case-ICU Communication Tool; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 7,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 8
States / cities: Birmingham, Alabama • Davis, California • Atlanta, Georgia + 5 more

Conditions: Open Angle Glaucoma
Interventions: CycloPen Cyclodialysis System; Device
Lead sponsor: Iantrek, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 15
States / cities: Newport Beach, California • Cape Coral, Florida • DeLand, Florida + 12 more

Conditions: Aphakia Cataract
Interventions: Light Adjustable lens (LAL) and Light Delivery Device (LDD); Device
Lead sponsor: RxSight, Inc.; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 6
States / cities: Alexandria, Minnesota • Omaha, Nebraska • Dallas, Texas + 3 more

Conditions: Lung Transplant Failure and Rejection
Interventions: Not listed
Lead sponsor: University of Pennsylvania; Other
Eligibility: 13 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • San Francisco, California • Stanford, California + 7 more

Conditions: Child Obesity
Interventions: Child Safety Control Intervention, Responsive Parenting Intervention; Behavioral
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Not listed
Enrollment: 216 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Hershey, Pennsylvania • State College, Pennsylvania

Conditions: Retinopathy of Prematurity (ROP)
Interventions: rhIGF-1/rhIGFBP-3; Drug
Lead sponsor: Shire; Industry
Eligibility: 40 Weeks to 108 Weeks
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 4
States / cities: Mobile, Alabama • Greenville, North Carolina • Oklahoma City, Oklahoma + 1 more

Conditions: Coronary Artery Disease, Obesity
Interventions: Medium-intensity Minimally-directive Counseling; Behavioral
Lead sponsor: The Camelot Foundation; Other
Eligibility: 30 Years to 59 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Chicago, Illinois • Omaha, Nebraska

Conditions: Paroxysmal Atrial Fibrillation
Interventions: Not listed
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 364 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 25
States / cities: Birmingham, Alabama • Phoenix, Arizona • Burlingame, California + 18 more

Conditions: Prostate Cancer, Prostate Cancer (Diagnosis), High-risk Prostate Cancer, Localized Prostate Carcinoma, Very High Risk Prostate Carcinoma
Interventions: 177 Lutetium Prostate-Specific Membrane Antigen 617, Actinium-225 Prostate-Specific Membrane Antigen 617, Non-investigational, Prostatectomy, Prostate Tissue Collection, Single-photon emission computed tomography (SPECT)/Computerized tomography (CT), Blood Sample Collection; Drug · Procedure
Lead sponsor: Thomas Hope; Other
Eligibility: 18 Years and older · Male only
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Opioid Withdrawal, Chronic Pain
Interventions: Buprenorphine Patch, Placebo, Transcranial Magnetic Stimulation (TMS), Sham Transcranial Magnetic Stimulation (TMS); Drug · Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Lymphoma, Non-Hodgkins, Hodgkins Disease
Interventions: Not listed
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Adherence to Physical Activity After Completing Cardiac Rehabilitation (CR) in Older Adults
Interventions: Virtual Coaching and social support; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 55 Years to 100 Years
Enrollment: 286 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Achalasia
Interventions: Symptom questionnaire; Other
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alagille Syndrome, Progressive Familial Intrahepatic Cholestasis
Interventions: Livmarli; Drug
Lead sponsor: Mirum Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 8
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Disease, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions: Ataluren, PLACEBO; Drug
Lead sponsor: PTC Therapeutics; Industry
Eligibility: 5 Years and older · Male only
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 22
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 19 more

Conditions: Attenuated Familial Adenomatous Polyposis, Deleterious Familial Adenomatous Polyposis
Interventions: Chart Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: COVID-19, Invasive Malignancy (Any Type)
Interventions: Web-based REDCap survey; Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 19,275 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Polycythemia Vera, ET (Essential Thrombocythemia), Polycythemia Vera (PV), Essential Thrombocythemia (ET), Primary Myelofibrosis (MF), Primary Myelofibrosis (PMF), Myelofibrosis, Myelofibrosis (MF), Myelofibrosis, Primary, Myelofibrosis, Post ET, Myelofibrosis, Post PV, Myelofibrosis (PMF), Myelofibrosis，MF, Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis, Myelofibrosis Due to and Following Polycythemia Vera, Myelofibrosis Transformation in Essential Thrombocythemia, Myelofibrosis With High Molecular Risk Mutations, MF, Secondary Myelofibrosis, Secondary Myelofibrosis in Myeloproliferative Disease, Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis), Post-Polycythemia Vera Myelofibrosis, Post-polycythemia Vera Myelofibrosis (PPV-MF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), Post-polycythemia Vera Myelofibrosis(Post-PV MF), Post-PV MF, Post-Essential Thrombocythemia Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis(Post-ET MF), Post-essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-ET MF, Pre-fibrotic Myelofibrosis, Myeloproliferative Disorder, Myeloproliferative Disorders, Myeloproliferative Disorders (MPD), Myeloproliferative Neoplasms (MPNs), Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis, Myeloproliferative Neoplasm With 10% Blasts or Higher, Myeloproliferative Neoplasms, MPN, MPN (Myeloproliferative Neoplasms), MPN-associated Myelofibrosis, Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Not Otherwise Specified, Accelerated Phase MPN, Accelerated Phase Myeloproliferative Neoplasm, Blast Phase MPN, Blast Phase Myeloproliferative Neoplasm, Thrombocythemia Myelofibrosis (PET-MF), Thrombocythemia, Essential, Thrombocythemia, Hemorrhagic, Agnogenic Myeloid Metaplasia, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, MDS/MPN Crossover Syndromes
Interventions: Not listed
Lead sponsor: MPN Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2035
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Chronic Pain
Interventions: Spinal cord stimulation (SCS), Dorsal root ganglion stimulation (DRG); Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Timeline: 2019 – 2029
U.S. locations: 30
States / cities: Phoenix, Arizona • Tucson, Arizona • Larkspur, California + 24 more

Conditions: Stroke, Brain Disease, Vascular Diseases, Cerebrovascular Disorder
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia

The Effects of Treating Insomnia on Behavioral Weight Loss Outcomes in Survivors of Breast Cancer

Improving Diabetes Equity and Advancing Care Study

Heartfulness Meditation (HFM) in Cyclic Vomiting Syndrome (CVS)

A Communication Tool to Improve Communication in the ICU

Study of the CycloPen Micro-Interventional System and Long-Term Clinical Outcomes

Long-Term Clinical Outcomes Of Subjects Enrolled In The RxSight Light Adjustable Lens (LAL) And Light Delivery Device (LDD) New Enrollment Study

Long Term Follow up of the LTOG Cohort

Intervention Nurses Start Infants Growing on Healthy Trajectories (INSIGHT) - Long Term Follow-Up

Long-term Safety and Efficacy Outcome Study Comparing Children Previously Enrolled in Study ROPP-2008-01 for the Prevention of Retinopathy of Prematurity (ROP)

Cardiovascular Outcomes Of Diet Counseling

ADVENT Trial Long Term Outcomes Evaluating Atrial Fibrillation Progression Study

Comparison of 177Lu-PSMA-617 and 225Ac-PSMA-617

ACTION: Trial of Adding Buprenorphine, CBT, and TMS to Improve Outcomes of Long-Term Opioid Therapy for Chronic Pain

Health and Psychosocial Outcomes in Long-Term Lymphoma Survivors

Supportive Training After Cardiac Rehabilitation Including Virtual Engagement

Outcome of Symptoms in Patients Undergoing a Heller Myotomy

Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Non-Surgical Management of Attenuated and Deleterious (Classical) Familial Adenomatous Polyposis: A Long-term Surveillance Program

COVID-19 and Cancer Consortium Registry

MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)

Long-Term Real-World Outcomes Study on Patients Implanted With a Neurostimulator

Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Stroke